$1.11
Rallybio Corporation is a biotechnology business based in the US. Rallybio Corporation shares (RLYB) are listed on the NASDAQ and all prices are listed in US Dollars. Rallybio Corporation employs 25 staff and has a trailing 12-month revenue of around $299,000.
Our top picks for where to buy Rallybio stock
How to buy Rallybio Corporation stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – RLYB. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Rallybio Corporation stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Rallybio Corporation stock price (NASDAQ: RLYB)
Use our graph to track the performance of RLYB stocks over time.Rallybio Corporation shares at a glance
Latest market close | $1.10 |
---|---|
52-week range | $1.09 - $5.96 |
50-day moving average | $1.27 |
200-day moving average | $1.74 |
Wall St. target price | $10.50 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.78 |
Is it a good time to buy Rallybio Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Rallybio Corporation price performance over time
Historical closes compared with the close of $1.1 from 2024-09-03
1 week (2024-08-29) | -7.56% |
---|---|
1 month (2024-08-05) | -6.78% |
3 months (2024-06-05) | -31.68% |
6 months (2024-03-05) | -40.70% |
1 year (2023-09-05) | -79.74% |
---|---|
2 years (2022-09-02) | -90.43% |
3 years (2021-09-03) | 14.1 |
5 years (2019-09-01) | N/A |
Rallybio Corporation financials
Revenue TTM | $299,000 |
---|---|
Gross profit TTM | $0 |
Return on assets TTM | -38.54% |
Return on equity TTM | -67.39% |
Profit margin | 0% |
Book value | $1.93 |
Market Capitalization | $47.7 million |
TTM: trailing 12 months
Rallybio Corporation share dividends
We're not expecting Rallybio Corporation to pay a dividend over the next 12 months.
You may also wish to consider:
- Gilead Sciences (GILD.US) (3.9% forward annual dividend yield)
Rallybio Corporation share price volatility
Over the last 12 months, Rallybio Corporation's shares have ranged in value from as little as $1.09 up to $5.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rallybio Corporation's is -1.685. This would suggest that Rallybio Corporation's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Rallybio Corporation has bucked the trend.
To put Rallybio Corporation's beta into context you can compare it against those of similar companies.
- Moderna (MRNA.US): 1.662
- Gilead Sciences (GILD.US): 0.199
- Biogen (BIIB.US): -0.038
Rallybio Corporation overview
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut. .
Frequently asked questions
What percentage of Rallybio Corporation is owned by insiders or institutions?Currently 4.058% of Rallybio Corporation shares are held by insiders and 77.312% by institutions. How many people work for Rallybio Corporation?
Latest data suggests 25 work at Rallybio Corporation. When does the fiscal year end for Rallybio Corporation?
Rallybio Corporation's fiscal year ends in December. Where is Rallybio Corporation based?
Rallybio Corporation's address is: 234 Church Street, New Haven, CT, United States, 06510 What is Rallybio Corporation's ISIN number?
Rallybio Corporation's international securities identification number is: US75120L1008
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question